SCHEMBL206743

SCHEMBL206743

COc1cccc2sc(Nc3nc(-c4cccnc4)cs3)nc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.80
KMT2A Q03164 12/20 0.80
MAPT P10636 9/20 0.80
POLB P06746 4/20 0.80
GAA P10253 4/20 0.80
RAB9A P51151 8/20 0.67
LMNA P02545 5/20 0.67
TDP1 Q9NUW8 2/20 0.67
CASP3 P42574 2/20 0.67
NPSR1 Q6W5P4 2/20 0.67
SENP7 Q9BQF6 2/20 0.67
SENP6 Q9GZR1 2/20 0.67
USP2 O75604 1/20 0.67
TP53 P04637 1/20 0.67
ALOX15 P16050 1/20 0.67
OPRK1 P41145 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
NPC1 O15118 6/20 0.66
ALDH1A1 P00352 3/20 0.58
HPGD P15428 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206221 0.89 MEN1 (1.00) MEN1KMT2AMAPTPOLBGAA
SCHEMBL250600 0.86 RAB9A (0.64) MEN1KMT2AMAPTPOLBGAA
SCHEMBL14053326 0.80 RAB9A (1.00) MEN1KMT2AMAPTPOLBGAA
SCHEMBL7679868 0.79 MAPK1 (0.82) MEN1KMT2AMAPTPOLBGAA
SCHEMBL14059092 0.75 RAB9A (0.78) MEN1KMT2AMAPTPOLBGAA
SCHEMBL207233 0.75 MEN1 (0.83) MEN1KMT2AMAPTGAARAB9A
Bromide SCHEMBL14054264 0.74 RAB9A (0.76) MEN1KMT2AMAPTPOLBGAA
SCHEMBL207484 0.74 GAA (0.65) MEN1KMT2AMAPTPOLBGAA
SCHEMBL8740257 0.74 MEN1 (0.78) MEN1KMT2AMAPTPOLBGAA
SCHEMBL206426 0.74 SLC2A1 (0.66) MEN1KMT2AMAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885MAPT 2207/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885MAPT 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.